Home LiteratureArticle Details
PMID: 8627706 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en.

Journal of virology ·Vol. 70 ·No. 3 ·1996-03-00 ·Pages 1818-27

Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG

Abstract

The development of viral resistance to the neuraminidase (NA) inhibitor, 4-guanidino-Neu5Ac2en, of influenza viruses was studied by serial passage of A/Turkey/Minnesota/833/80 (H4N2) in Madin-Darby canine kidney cells in the presence of increasing concentrations of inhibitor. Resistant mutants selected after eight passages, had a 10,000-fold reduction in sensitivity to the inhibitor in plaque assays, but their affinity (1/Kd) to the inhibitor was similar to that of the parental virus. Electron microscopic analysis revealed aggregation of the mutant virus at the cell surface in the presence of the inhibitor. Sequence analysis established that a substitution had occurred in the NA (Arg-249 to Lys) and in the HA2 subunit of the hemagglutinin (Gly-75 to Glu), in the vicinity of the proposed second sialic acid binding site. The change of residue 249 appears to be a chance mutation, for we were unable to reisolate this mutant, whereas subsequent experiments indicate changes in the hemagglutinin. After 13 passages of the parental virus, mutants that were resistant to the high concentrations of inhibitor tested were obtained. These viruses retained their drug-resistant phenotype even after five passages without the inhibitor. Electron microscopic analysis revealed no aggregation of virus on the surface of infected cells in the presence of the inhibitor. Sequence analysis of the NA gene from these drug-resistant mutants revealed an additional substitution of Glu to Ala at the conserved amino acid residue 119. This substitution is responsible for reducing the affinity of the inhibitor to the NA. Our findings suggest that the emergence of mutants resistant to 4-guanidine-Neu5Ac2en is a multistep process requiring prolonged exposure to the inhibitor.

MeSH Terms
Animals Antiviral Agents/pharmacology Base Sequence Cell Line DNA, Viral Dogs Drug Resistance, Microbial/genetics Enzyme Inhibitors/pharmacology Guanidines Influenza A virus/drug effects,enzymology,genetics,ultrastructure Molecular Sequence Data Mutation Neuraminidase/antagonists & inhibitors,chemistry Pyrans Sialic Acids/pharmacology Turkeys/virology Zanamivir
Chemicals
Antiviral Agents DNA, Viral Enzyme Inhibitors Guanidines Pyrans Sialic Acids Neuraminidase Zanamivir
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Gubareva L V
Department of Virology/Molecular Biology, St Jude Children's Research Hospital, Memphis, Tennessee 38101, USA.
Bethell R
Hart G J
Murti K G
Penn C R
Webster R G
References (28)
28 references, click to expand
  1. Evidence for host-cell selection of influenza virus antigenic variants.
    Nature. 1983 Jun 23-29;303(5919):706-9 PMID: 6190093
  2. Structure of the catalytic and antigenic sites in influenza virus neuraminidase.
    Nature. 1983 May 5-11;303(5912):41-4 PMID: 6188957
  3. Biologic potential of amantadine-resistant influenza A virus in an avian model.
    J Infect Dis. 1989 Jun;159(6):1050-6 PMID: 2723453
  4. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.
    N Engl J Med. 1989 Dec 21;321(25):1696-702 PMID: 2687687
  5. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2).
    Am J Epidemiol. 1991 Nov 1;134(9):988-97 PMID: 1951297
  6. Crystallographic detection of a second ligand binding site in influenza virus hemagglutinin.
    Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):324-8 PMID: 1729702
  7. Rational design of potent sialidase-based inhibitors of influenza virus replication.
    Nature. 1993 Jun 3;363(6428):418-23 PMID: 8502295
  8. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position.
    Glycoconj J. 1993 Feb;10(1):40-4 PMID: 8358225
  9. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.
    Antimicrob Agents Chemother. 1993 Jul;37(7):1473-9 PMID: 8363379
  10. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid.
    Antiviral Res. 1994 Aug;24(4):351-6 PMID: 7993078
  11. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding.
    J Virol. 1995 Feb;69(2):1099-106 PMID: 7815489
  12. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase).
    Antimicrob Agents Chemother. 1994 Oct;38(10):2270-5 PMID: 7840556
  13. Influenza virus neuraminidase: structure, antibodies, and inhibitors.
    Protein Sci. 1994 Oct;3(10):1687-96 PMID: 7849585
  14. 2,3-didehydro-2,4-dideoxy-4-guanidino-N-acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus.
    Biochem Mol Biol Int. 1995 Jul;36(4):695-703 PMID: 8528132
  15. The determination of enzyme inhibitor constants.
    Biochem J. 1953 Aug;55(1):170-1 PMID: 13093635
  16. In vivo selection of an influenza A2 strain resistant to amantadine.
    Nature. 1970 Apr 4;226(5240):82-3 PMID: 5434369
  17. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures.
    Bull World Health Organ. 1973;48(2):199-202 PMID: 4541685
  18. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase.
    Virology. 1974 Oct;61(2):397-410 PMID: 4472498
  19. Susceptibility of different strains of influenza A virus to the inhibitory effects of 2-deoxy-2,3-dehydro-n-trifluoracetylneuraminic acid (FANA).
    Virology. 1975 Jan;63(1):98-104 PMID: 1167433
  20. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action.
    J Gen Virol. 1976 Oct;33(1):159-63 PMID: 978183
  21. Amantadine-resistance as a genetic marker for influenza viruses.
    J Gen Virol. 1977 Aug;36(2):249-55 PMID: 561163
  22. Effects of sialylation of influenza virions on their interactions with host cells and erythrocytes.
    Virology. 1978 Jul 15;88(2):314-24 PMID: 567887
  23. Electrophoretic analysis of iodine-labeled influenza virus RNA segments.
    Anal Biochem. 1980 Feb;102(1):228-32 PMID: 7356157
  24. Plaque inhibition assay for drug susceptibility testing of influenza viruses.
    Antimicrob Agents Chemother. 1980 May;17(5):865-70 PMID: 7396473
  25. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.
    Nature. 1981 Jan 29;289(5796):366-73 PMID: 7464906
  26. Infectious entry pathway of influenza virus in a canine kidney cell line.
    J Cell Biol. 1981 Dec;91(3 Pt 1):601-13 PMID: 7328111
  27. Effects of hexose starvation and the role of sialic acid in influenza virus release.
    Virology. 1983 Mar;125(2):324-34 PMID: 6836915
  28. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1.
    J Virol. 1986 Aug;59(2):377-83 PMID: 3016304
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1996-03-00
Pages
1818-27
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC190009
Subset
IM
Grants
NIAID NIH HHS · AI-08831 · United States
NCI NIH HHS · CA-21765 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com